Scope
Selected recommendations from the 2021 KDIGO glomerular-disease guideline cover diagnostic assessment, nephrotic complications, adult membranous nephropathy, adult minimal change disease, adult focal segmental glomerulosclerosis and adult anti-GBM disease. Treatment depends on the clinical syndrome, disease activity and risk of toxicity, rather than the biopsy label alone.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Assess the syndrome and treatment risks
- Kidney biopsy is the diagnostic standard for glomerular disease, although selected circumstances permit treatment without biopsy confirmation. Repeat biopsy when its information could change treatment or prognosis. [1]
- Quantify proteinuria before starting or intensifying immunosuppression, or after a change in clinical status, using a 24-hour urine collection in adults. In children, use a first-morning protein–creatinine ratio. Examine urine sediment for erythrocyte morphology, red-cell casts and/or acanthocytes in glomerular disease. [1]
- Treat thromboembolic events occurring with nephrotic syndrome with full anticoagulation. Use prophylactic anticoagulation only when the thromboembolic risk exceeds the patient-specific risk of serious bleeding from anticoagulation. [1]
- Screen clinically appropriate patients with glomerular disease for tuberculosis, hepatitis B and C, HIV and syphilis. Consider trimethoprim–sulfamethoxazole prophylaxis during high-dose prednisone or immunosuppressants such as rituximab or cyclophosphamide. [1]
- Coordinate pregnancy care for glomerular disease between nephrology and obstetrics, ideally beginning the planning before pregnancy. [1]
Use risk-based care for membranous nephropathy
- A kidney biopsy is not required to confirm membranous nephropathy in a patient who has nephrotic syndrome and a positive anti-PLA2R antibody test. Evaluate for associated conditions whether anti-PLA2R or anti-THSD7A antibodies are present or absent. [1]
- Give all patients with primary membranous nephropathy and proteinuria optimal supportive care. Immunosuppression is unnecessary when proteinuria is below 3.5 g/day AND albumin exceeds 30 g/L by bromocresol-purple or immunometric assay AND eGFR exceeds 60 mL/min/1.73 m2. [1]
- In membranous nephropathy with nephrotic syndrome and normal eGFR, immunosuppression is not required unless a progression risk factor or serious nephrotic complication is present, such as acute kidney injury, infection or thromboembolism. [1]
- For membranous nephropathy with at least one progression risk factor, KDIGO recommends rituximab, cyclophosphamide with alternate-month glucocorticoids for 6 months, or a calcineurin-inhibitor-based regimen for at least 6 months. Choose according to estimated risk; these are not interchangeable regimens for every risk category (1B). [1]
- In membranous nephropathy, anti-PLA2R levels at 6 months after starting therapy may help judge response and guide adjustments. Persistent proteinuria alone does not establish resistance; consider biopsy to document activity when proteinuria persists despite normal or near-normal albumin or loss of anti-PLA2R antibodies. [1]
Treat adult minimal change disease
- Diagnose adult minimal change disease by kidney biopsy. KDIGO recommends high-dose oral glucocorticoids for initial treatment (1C). [1]
- For adult minimal change disease, limit high-dose glucocorticoids to no longer than 16 weeks and begin tapering 2 weeks after complete remission. If glucocorticoids are relatively contraindicated, consider initial cyclophosphamide, a calcineurin inhibitor or mycophenolate mofetil. [1]
- Treat infrequent adult minimal-change relapses with glucocorticoids. For frequently relapsing or steroid-dependent disease, KDIGO recommends cyclophosphamide, rituximab, calcineurin inhibitors or mycophenolic-acid analogues instead of prednisone alone or no treatment (1C). [1]
Distinguish adult FSGS subtypes before immunosuppression
- Evaluate adults with an FSGS lesion but no nephrotic syndrome for a secondary cause. Genetic testing may benefit selected patients; refer them to centres with relevant expertise for assessment. [1]
- Do not use immunosuppression for adult FSGS of undetermined cause or secondary FSGS. Provide supportive treatment for persistent proteinuria, including renin–angiotensin-system blockade, blood-pressure control and dietary salt restriction, and treat the underlying secondary cause. [1]
- For adult primary FSGS, KDIGO recommends high-dose oral glucocorticoids first line (1D). Continue the initial high dose until complete remission or as tolerated for a maximum of 16 weeks, whichever is earlier. Responders should receive a total glucocorticoid course of at least 6 months. [1]
- In adults with primary FSGS and relative contraindications or intolerance to glucocorticoids, consider a calcineurin inhibitor as the initial immunosuppressive treatment. [1]
- For adult steroid-resistant primary FSGS, KDIGO recommends cyclosporine or tacrolimus for at least 6 months instead of continuing glucocorticoid monotherapy or giving no treatment (1C). Responders should receive the calcineurin inhibitor for at least 12 months to reduce relapse risk. [1]
- When titrating a calcineurin inhibitor for adult primary FSGS, balance proteinuria response against kidney toxicity. Reduce the dose if creatinine rises without plateauing or increases more than 30% above baseline; discontinue if creatinine fails to fall after dose reduction. [1]
- Refer adults with steroid-resistant primary FSGS who resist or cannot tolerate calcineurin inhibitors to a specialist centre to consider repeat biopsy, alternative treatment or a clinical trial. [1]
Act urgently in adult anti-GBM disease
- Investigate suspected rapidly progressive glomerulonephritis for anti-GBM disease without delay. If anti-GBM disease is suspected, start treatment without waiting for diagnostic confirmation. [1]
- For adult anti-GBM glomerulonephritis, KDIGO recommends cyclophosphamide plus glucocorticoids and plasma exchange (1C). The exception requires ALL of: dialysis at presentation; an adequate biopsy showing 100% crescents OR more than 50% global glomerulosclerosis; and no pulmonary haemorrhage. [1]
- In anti-GBM disease, continue plasma exchange until antibody titres are undetectable. Give cyclophosphamide for 2–3 months and glucocorticoids for about 6 months. Routine maintenance is unnecessary for anti-GBM disease alone; patients also positive for ANCA require maintenance as for ANCA-associated vasculitis. [1]
- Postpone kidney transplantation after kidney failure from anti-GBM disease until anti-GBM antibodies have remained undetectable for at least 6 months. [1]
Limitations and use
- This is a focused summary of selected 2021 chapters, not a complete contemporary guide to every glomerular disease. Later disease-specific KDIGO guidance should be used for IgA nephropathy/IgA vasculitis, childhood nephrotic syndrome, ANCA-associated vasculitis and lupus nephritis; their older treatment chapters are not summarized here.
- Detailed drug doses, monitoring schedules, pregnancy medication choices, infection-related disease, complement-mediated disease, transplantation protocols and image-only treatment algorithms are outside this summary. Recommendations for adult MCD, FSGS and anti-GBM disease should not be transferred to children.
- Membranous-nephropathy risk categories and anticoagulant decisions require individualized assessment. Serum-albumin thresholds depend on the laboratory assay; this summary does not provide a stand-alone anticoagulant selection or dosing rule.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Glomerular diseases: final 2021 clinical practice guideline
Selected recommendation material consulted
Publication details
- Issuing organisation
- KDIGO
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: glomerular diseases kdigo
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.